Drug firm Lupin today said it has received the US Food and Drug Administration's approval for marketing and distributing Lamotrigine tablets, used for treating bipolar disorders, in American markets.
The company has received approval for Lamotrigine tablets in 25 mg, 100 mg, 150 mg and 200 mg strengths.
Lamotrigine tablets are the generic version of GlaxoSmithKline's Lamictal tablets with an annual sales worth $452 million for the twelve month period ended March 2010, Lupin said quoting market research firm IMS.